Redox-directed cancer therapeutics: Taurolidine and piperlongumine as broadly effective antineoplastic agents (Review)

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1329-1336

  Möhler, Hanns ^a   Pfirrmann, Rolf W ^b   Frei, Karl ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Geistlich Pharma AG   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antineoplastic agent; Apoptosis; Autophagy; Necroptosis; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; GLUTATHIONE; PIPERLONGUMINE; REACTIVE OXYGEN METABOLITE; TAUROLIDINE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; PIPERLONGUMININE; TAURINE; THIADIAZINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOPHAGY; BONE MARROW CELL; CANCER CELL LINE; CANCER RESISTANCE; CANCER STEM CELL; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; FIBROBLAST; GLIOBLASTOMA; HUMAN; MESOTHELIUM CELL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NECROPTOSIS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PERIOPERATIVE PERIOD;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DIOXOLANES; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; PERIOPERATIVE CARE; REACTIVE OXYGEN SPECIES; TAURINE; THIADIAZINES;

EID: 84907463390     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2566     Document Type: Review

References (72)

1. Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837, 2009.
2. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
3. Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931-947, 2013.
4. Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007. (Pubitemid 46340350)
5. Sporn MB and Liby KT: NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.
6. Wondrak GT: Redox-directed cancer therapeutics: molecular merchanisms and opportunities. Antioxid Redox Signal 11: 3013-3069, 2009.
7. Kansanen E. Kuosmanen SM, Leinonen H and Levonen AL: The Keap1-Nrf2 pathway: mechanism of activation and dysregulation in cancer. Redox Biology 1: 45-49, 2013.
8. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Jänisch W and Brock M: Treatment of glioblastoma with intravenous Taurolidine. First clinical experience. Anticancer Res 24: 1143-1147, 2004. (Pubitemid 38624954)
9. Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent Taurolidine. Report of a case. World J Surg Oncol 4: 34, 2006.
10. McCartney AC and Browne MK: Clinical studies on administration of taurolidine in severe sepsis: a preliminary study. Progr Clin Biol Res 272: 361-371, 1988.
11. Staubach KH: Adjuvant therapy of peritonitis with taurolidine. Modulation of mediator liberation. Langenbecks Arch Chir 382: S26-S30, 1997.
12. Braumann C, Gutt CN, Scheele J, Menenakos C, Willems W, Mueller JM and Jacobi CA: Taurolidine reduces the tumor-stimulating cytokine IL 1beta in patients with resectable gastrointestinal cancer: a multicenter prospective randomized trial. World J Surg Oncol 7: 32-45, 2009.
13. Wesch G, Petermann C and Linder MM: Drug therapy of peritonitis: 6-year experience with the chemotherapeutic agent and anti-endotoxin Taurolin. Fortschr Med 101: 545-550, 1983. (Pubitemid 13109652)
14. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL and Lee SW: Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011.
15. Parkinson EI and Hergenrother PJ: Runaway ROS as selective anticancer strategy. Chem Med Chem 6: 1957-1959, 2011.
16. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
17. Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
18. Pfirrmann RW: Taurolin, ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Brückner WL and Pfirrmann RW (eds). Urban and Schwarzenberg Verlag, 1985 (In German).
19. Rodak R, Kubota H, Ishihara H, Eugster HP, Könü D, Möhler H, Yonekawa Y and Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by Taurolidine. J Neurosurg 102: 1055-1068, 2005. (Pubitemid 43193975)
20. Stendel R, Biefer HR, Dékany M, Kubota H, Münz C, Wang S, Möhler H, Yonekawa Y and Frei K: The antibacterial substance Taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 5: 194-210, 2009.
21. Calabresi P, Goulette FA and Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61: 6816-6821, 2001. (Pubitemid 32896506)
22. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L and Gaudio G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J 34: 1399-1407, 2009.
23. Nici L, Monfils B and Calabresi P: The effects of Taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10: 7655-7661, 2004. (Pubitemid 39557529)
24. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W and Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 56: 327-336, 2007. (Pubitemid 46679090)
25. Darnowski JW, Goulette FA, Cousens LP, Chatterjee D and Calabresi P: Mechanistic and antineoplastic evaluation of Taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 54: 249-258, 2004. (Pubitemid 39141742)
26. Stendel R, Stoltenburg-Didinger G and Brock M: Apoptotic changes in brain tumor cells induced by Taurolidine. J Cancer Res Clin Oncol 128: 150, 2002.
27. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattroth M and Brock M: The effect of Taurolidine on brain tumor cells. Anticancer Res 22: 809-814, 2002. (Pubitemid 34475233)
28. Ribizzi I, Darnowski JW, Goulette FA, Akhtar MS, Chatterjee D and Calabresi P: Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. Bone Marrow Transplant 29: 313-319, 2002. (Pubitemid 34229036)
29. McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 7: 685-691, 2000.
30. Nestler G, Schulz HU, Schubert D, Krüger S, Lippert H and Pross M: Impact of Taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats. Surg Endosc 19: 280-284, 2005. (Pubitemid 40685202)
31. Braumann C, Schoenbeck M, Menenakos C, Kilian M and Jacobi CA: Effects of increasing doses of a bolus injection and an intravenous long-term therapy of Taurolidine on subcutaneous (metastic) tumor growth in rats. Clin Exp Metastasis 22: 77-83, 2005. (Pubitemid 41185864)
32. Hoksch B, Rufer B, Gazdhar A, Bilici M, Beshay M, Gugger M and Schmid RA: Taurolidine in the prevention and therapy of lung metastases. Eur J Cardiothorac Surg 36: 1058-1063, 2009.
33. Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W and Mittelkötter U: Synergistic effects in apoptosis induction by Taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Investigat Surg 20: 339-348, 2007.
34. Jacobi C, Peter FJ, Wenger FA, Ordemann J and Müller JM: New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg 16: 393-399, 1999. (Pubitemid 29520956)
35. Jacobi C, Sabat R, Ordemann J, Wenger F, Volk H and Müller J: Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model. Langenbecks Arch Chir 382: S31-S36, 1997. (Pubitemid 28006199)
36. Jacobi CA, Ordemann J, Böhm B, Zieren HU, Sabat R and Müller JM: Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am J Surgery 174: 359-363, 1997. (Pubitemid 27415373)
37. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U and Hofmann M: The tumor suppressive reagent Taurolidine inhibits growth of malignant melanoma - a mouse model. J Surg Res 143: 372-378, 2007. (Pubitemid 350101573)
38. Sun BS, Wang JH, Liu LL, Gong SL and Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol 96: 241-248, 2007.
39. Walters DK, Muff R, Langsam B, Gruberer P, Born W and Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osterosarcoma cell lines. Invest New Drugs 25: 305-312, 2007. (Pubitemid 46944855)
40. Marley K, Helfand SC, Edris WA, Mata JE, Gitelman AI, Medlock J and Séguin B: The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro. BMC Veterinary Res 9: 15-24, 2013.
41. Chromik AM, Daigeler A, Bulut D, Flier A, May C, Havati K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter U, Hahn SA and Uhl W: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Cancer Res 29: 21-37, 2010.
42. Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W and Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol 32: 1205-1220, 2008.
43. Daigeler A, Chromik AM, Haendschke K, Emmelmann S, Siepmann M, Hensel K, Schmitz G, Klein-Hitpass L, Steinau HU, Lehnhardt M and Hauser J: Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma. Ultrasound Med Biol 36: 1893-1906, 2010.
44. Jacobi CA, Menenakos C and Braumann C: Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 16: 917-921, 2005. (Pubitemid 41416082)
45. Volz J, Volz-Köster S, Kanis S, Klee D, Ahlert C and Melchert F: Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model. Cancer 89: 262-266, 2000. (Pubitemid 30489872)
46. Da Costa ML, Redmond HP and Bouchier-Hayes DJ: Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 101: 111-119, 2001. (Pubitemid 34044548)
47. Chromik AM, Daigeler A, Bulut D, Flier A, May C, Harti K, Roschinsky J, Sülberg D, Ritter PR, Mittelkötter U, Hahn SA and Uhl W: Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines. J Exp Clin Res 29: 21-36, 2010.
48. Chen L, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526, 2012.
49. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Acxhanta G, Arlinghaus RB, Liu J and Hunag P: Selective killing of oncogenically trandformed cells through a ROS mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006. (Pubitemid 44311067)
50. Huang P, Feng L, Oldham EA, Keating MJ and Plunkett W: Superoxide dismutase as a target for killing of cancer cells. Nature 407: 390-395, 2000.
51. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N and Jacks T: Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 108: 8773-8778, 2011.
52. Dolam S, Lessnick SL, Hahn WC and Stockwell BR: Idebtificaton of genotype-selective antitumor agents using syntheticchemical screening in engineered human tumor cells. Cancer Cell 3: 285-296, 2003. (Pubitemid 37443883)
53. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennet JM, etal : An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110: 4427-4435, 2007. (Pubitemid 351377809)
54. O'Brien G, Cahill R, Bouchier-Hayes D and Redmond P: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Irish J Med Sci 175: 10-14, 2006.
55. Doddakula KK, Neary PM, Wang JH, Sookhai S, O'Donnel A, etal: The antioxidant agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine. Surgery 148: 567-572, 2010.
56. Braumann C, Guenther N, Pohlenz J, Pfirrmann RW and Menenakos C: Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine. Eur Surg Res 42: 91-96, 2009.
57. Neary PM, Hallihan P, Wang JH, Pfirrmann R, Bouchier-Haves HP and Redmond HP: The evolving role of Taurolidine in cancer therapy. Ann Surg Oncol 17: 1135-1143, 2010.
58. Liberko M, Kolostova K and Bobek V: Essentials of circulating tumor cells for clinical research and practice. Cirtic Rev Hematol Oncol 88: 338-356, 2013.
59. Kilian M, Gregor JI, Heukamp I, Braumann C, Guski H, Schimke I, Walz MK, Jacobi CA and Wenger FA: Impact of taurolidine and octreotide on liver metastasis and lipid peroxidation after laparoscopy in chemical induced ductal pancreatic cancer. Invest New Drugs 23: 157-164, 2005. (Pubitemid 40386233)
60. Gong L, Greenberg HE, Perhach JL, Waldman SA and Kraft WK: The pharmacokinetics of Taurolidine metabolites in healthy volunteers. J Clin Pharmacol 47: 697-703, 2007. (Pubitemid 46800427)
61. Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann R, Fiss I, Möhler H and Bigler L: Pharmacokinetics of Taurolidine follwing repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives Taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinetics 46: 513-524, 2007. (Pubitemid 46827860)
62. Chromik AM, Hahn SA, Daigeler A, Flier A, Bulut D, May C, Harati K, Roschinsky J, Sülberg D, Weyhe D, Mittelkötter U and Uhl W: Gene expression analysis of cell death induction by taurolidine in different malignant cell lines. BMC Cancer 10: 595-608, 2010.
63. Daigeler A, Brenzel Ch, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinsträsser L, Klein-Hitpass L, Mittelkötter U, Uhl W and Chromik AM: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res 27: 82-102, 2008.
64. Rubinsztein DC, Codogno P and Levine B: Autophagy modulation as a potential therapeutic target for divers diseases. Nature Rev Drug Disc 11: 709-730, 2012.
65. Möhler T, Willhauck-Fleckenstein M, Schwartz-Albiez R, Merling A and Möhler H: Inhibition of endothelial cell adhesion and in vitro angiogenesis by Taurolidine. Cancer Ther 6: 623-628, 2008.
66. Egan BM, Bouchier-Hayes DJ, Condron C, Kelly CJ and Abdih H: Taurolidine attenuates the hemodynamic and respiratory changes associated with endotoxemia. Scock 17: 308-311, 2002.
67. Bedrosian I, Sofia RD, Wolff SM and Dinarello CA: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3: 568-575, 1991.
68. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell 140: 883-899, 2010.
69. Reddy PS, Jamil K, Madhusudhan P and Anjani G: Antibacterial activity of isolates of from Piper longum and Taxus baccata. Pharm Biol 39: 236-238, 2001. (Pubitemid 32881537)
70. Adams DJ, Dai M, Pellegrino G, Wagner BK, et al: Synthesis, cellular evaluation and mechanism of action of piperlongumine anlogs. Proc Natl Acad Sci USA 109: 15115-15120, 2012.
71. Wang Y, Wang JW, Xiao X, Shan Y, Xue B, Jiang G, He Q, Chen J, Xu HG, Zhao RX, Werle KD, Cui R, Liang J, Li YL and Xu ZX: Piperlongumine induces autophagy by targeting p38. Cell Death Dis 4: e824, 2013.
72. Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A and Kolenko VM: Piperlongumine inhibits NFkappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 73: 1-10, 2013.